Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis (Q35134579)

6 August 2017

1 reference

title

Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis (English)

1 reference

6 August 2017

Clostridium difficile

object named as

Clostridium difficile

1 reference

1

Mark H Wilcox

1 reference

6 August 2017

1 June 2003

1 reference

Best Practice and Research: Clinical Gastroenterology

6 August 2017

1 reference

6 August 2017

17

1 reference

6 August 2017

3

1 reference

6 August 2017

475-493

1 reference

The distribution of Clostridium difficile in the environment of South Wales.

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

When stool cultures from adult inpatients are appropriate

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

The diagnosis of Clostridium difficile-associated disease

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Usefulness of simultaneous detection of toxin A and glutamate dehydrogenase for the diagnosis of Clostridium difficile-associated diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Evaluation of biosite triage Clostridium difficile panel for rapid detection of Clostridium difficile in stool samples

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

The diagnosis of Clostridium difficile-associated diarrhea: comparison of Triage C. difficile panel, EIA for Tox A/B and cytotoxin assays

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Treatment of antibiotic-associated pseudomembranous colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Treatment of antibiotic-associated colitis with vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Clostridium difficile infection: responses, relapses and re-infections

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Factors associated with prolonged symptoms and severe disease due to Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Financial burden of hospital-acquired Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

The epidemiology and typing of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Community-acquired Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Incidence and impact of Clostridium difficile infection in the UK, 1993-1996.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Typing of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Analysis of Clostridium difficile isolates from nosocomial outbreaks at three hospitals in diverse areas of Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Management and control of a large outbreak of diarrhoea due to Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Epidemiology of antibiotic-associated colitis; isolation of Clostridium difficile from the hospital environment

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Is Clostridium difficile endemic in chronic-care facilities?

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Molecular epidemiology of endemic Clostridium difficile infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Prospective evaluation of environmental contamination by Clostridium difficile in isolation side rooms

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Bacterial contamination of uniforms.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Reduction in vancomycin-resistant Enterococcus and Clostridium difficile infections following change to tympanic thermometers

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

A randomized crossover study of disposable thermometers for prevention of Clostridium difficile and other nosocomial infections

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

An in-vitro model of colonisation resistance to Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Pathogenesis of Clostridium difficile infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Clostridium difficile infection in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Extended spectrum cephalosporins and Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: a four-year survey in a general hospital.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Faecal concentrations of piperacillin and tazobactam in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Surgical antibiotic prophylaxis and Clostridium difficile toxin positivity

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Epidemiology of diarrhoea caused by enterotoxigenic Clostridium perfringens

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Evidence for antibiotic induced Clostridium perfringens diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Laboratory diagnosis of Clostridium perfringens antibiotic-associated diarrhoea.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Analysis of the pathogenicity locus in Clostridium difficile strains

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Multicenter evaluation of the Clostridium difficile TOX A/B TEST.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Serum antibody response to toxins A and B of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Hospital-acquired Clostridium difficile diarrhoea and herd immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

An antibiotic policy associated with reduced risk of Clostridium difficile-associated diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Effectiveness of liquid soap vs. chlorhexidine gluconate for the removal of Clostridium difficile from bare hands and gloved hands

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Hand contamination before and after different hand hygiene techniques: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Environmental control to reduce transmission of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Acquisition of Clostridium difficile from the hospital environment

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Hospital disinfectants and spore formation by Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Reduced susceptibility of Clostridium difficile to metronidazole.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Relapse versus reinfection withClostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Recurrence of symptoms in Clostridium difficile infection--relapse or reinfection?

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Saccharomyces boulardii fungemia in a patient receiving Ultra-levure therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.).

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Treatment of Clostridium difficile diarrhoea with brewer's yeast

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Clostridium difficile diarrhea and colonization after treatment with abdominal infection regimens containing clindamycin or metronidazole

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Metronidazole may inhibit intestinal colonization with Clostridium difficile.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Intravenous immunoglobulin therapy for severe Clostridium difficile colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900017-9

7 January 2021

10.1016/S1521-6918(03)00017-9

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12763508